Answers are grounded in this paper and cite their sources.
Despite advances in immunotherapy (IO) and radiation therapy (RT), anti-PD-1 (aPD-1) therapy has provided only modest benefit in head and neck squamous cell carcinoma (HNSCC) for reasons that remain poorly understood. CCR8 is a chemokine receptor selectively enriched on tumor infiltrating regulatory T cells (Tregs), making it an attractive candidate for therapeutic targeting. Given our knowledge that immunosuppressive T-regulatory cells are associated with resistance to RT and IO, but have no effective targeting strategy in HNSCC, we investigate the depletion of tumor specific Treg subsets on tumor growth in female mice. In human and murine HNSCC, we characterize a subset of CCR8+ Tregs that are an immunosuppressive cell population associated with incomplete response to RT and IO. In preclinical models of HNSCC, we find that RT drives CCR8+ Treg infiltration into the primary tumor to promote tumor growth and recurrence, which can be reversed with administration of CCR8-depleting antibodies (aCCR8). Finally, we show that resistance to RT+aPD1 combination therapy is mediated by aPD1 activation of CCR8+ Tregs to facilitate tumor growth, which can be reversed with aCCR8. These findings reveal the immunosuppressive profile of CCR8+ Tregs in HNSCC and pave the way for novel combination strategies of IO in HNSCC. Previous evidence has implicated regulatory T cells (Tregs) in treatment resistance in head and neck cancer. Here the authors report that radiotherapy and anti-PD1 therapy drive the accumulation and activation of intratumoral CCR8+ Tregs, promoting tumor growth and recurrence, which can be reversed with administration of CCR8 depleting antibodies.
No takes yet. Share an insight, caveat, or question.
Olimpo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: